<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755985</url>
  </required_header>
  <id_info>
    <org_study_id>AD-213PK/PD-02</org_study_id>
    <nct_id>NCT04755985</nct_id>
  </id_info>
  <brief_title>A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132</brief_title>
  <official_title>A Randomized, Open Label, Multi Dose, Cross Over Design Clinical Study to Evaluate the Pharmacokinetic Pharmacodynamic Characteristics and Safety of AD-213-B and AD-2132 After Oral Administration in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare safety, pharmacokinetics and pharmacodynamics of AD-213-B to AD-2132 in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Actual">July 23, 2021</completion_date>
  <primary_completion_date type="Actual">May 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>From Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of Integrated gastric acidity(%) from baseline</measure>
    <time_frame>4 times from Day -1 to Day 17</time_frame>
    <description>Evaluation PD after multiple dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation PK after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdss/F</measure>
    <time_frame>Day 1 up to Day 17</time_frame>
    <description>Evaluation PK after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Integrated gastric acidity(mmolâˆ™hr/L) from baseline</measure>
    <time_frame>4 times from Day -1 to Day 17</time_frame>
    <description>Evaluation PD after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time to maintain gastric pH 4.0 or higher</measure>
    <time_frame>4 times from Day -1 to Day 17</time_frame>
    <description>Evaluation PD after multiple dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gastroesophagus Reflux Disease</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-213-B</intervention_name>
    <description>1 tablet administered before the breakfast during 5 days</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-2132</intervention_name>
    <description>1 tablet administered before the breakfast during 5 days</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults over 19 years of age.&#xD;
&#xD;
          -  Weight is more than 50kg and BMI is more than 18.0 kg/m^2 , no more than 27.0 kg/m^2.&#xD;
&#xD;
          -  Subject who has been judged to be eligible for clinical laboratory tests and&#xD;
             electrocardiogram tests such as serum tests, hematology tests, blood chemistry tests,&#xD;
             and urinary tests conducted within four weeks prior to the administration of clinical&#xD;
             trials.&#xD;
&#xD;
          -  Subjects who has heard and fully understood the detailed description of this clinical&#xD;
             trial and have willingness to sign of informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject who has a history that can affect the absorption, distribution, metabolism,&#xD;
             or excretion of a drug.&#xD;
&#xD;
          -  As a result of laboratory tests, the following figures: ALT or AST or total bilirubin&#xD;
             &gt; 1.5 times upper limit of normal range.&#xD;
&#xD;
          -  As a result of laboratory tests, the following figures: Creatinine clearance &lt;&#xD;
             80mL/min.&#xD;
&#xD;
          -  Subjects who judged ineligible by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Young-Ran Yoon</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

